{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:50:52Z","timestamp":1740178252223,"version":"3.37.3"},"reference-count":8,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,27]]},"DOI":"10.1182\/bloodadvances.2024012918","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T15:31:29Z","timestamp":1724772689000},"page":"4447-4448","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Ending endless follow-up for low-risk CLL?"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2086-6031","authenticated-orcid":false,"given":"Philip A.","family":"Thompson","sequence":"first","affiliation":[{"name":"1Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"},{"name":"2The Sir Peter MacCallum Department of Clinical Oncology, The University of Melbourne, Parkville, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"16","key":"2024082715311981600_bib1","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1182\/bloodadvances.2023012382","article-title":"It is\u00a0feasible and safe to stop specialized follow-up of asymptomatic lower\u00a0risk chronic lymphocytic leukemia","volume":"8","author":"Brieghel","year":"2024","journal-title":"Blood Adv"},{"issue":"5","key":"2024082715311981600_bib2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/ejh.13743","article-title":"Identifying patients with chronic lymphocytic leukemia without need of treatment: end of endless watch and wait?","volume":"108","author":"Brieghel","year":"2022","journal-title":"Eur J Haematol"},{"issue":"6","key":"2024082715311981600_bib3","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","author":"CLL-IPI Working Group","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"2024082715311981600_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12938-021-00973-6","article-title":"The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019","volume":"21","author":"Yao","year":"2022","journal-title":"Biomed Eng Online"},{"issue":"11","key":"2024082715311981600_bib5","doi-asserted-by":"crossref","first-page":"e499","DOI":"10.1038\/bcj.2016.105","article-title":"Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients","volume":"6","author":"da Cunha-Bang","year":"2016","journal-title":"Blood Cancer J"},{"key":"2024082715311981600_bib6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2147\/CLEP.S99486","article-title":"The Danish National Chronic Lymphocytic Leukemia Registry","volume":"8","author":"da Cunha-Bang","year":"2016","journal-title":"Clin Epidemiol"},{"issue":"2","key":"2024082715311981600_bib7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood.2021010845","article-title":"The CLL12 trial: ibrutinib vs placebo in treatment-na\u00efve, early-stage chronic lymphocytic leukemia","volume":"139","author":"Langerbeins","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2024082715311981600_bib8","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1159\/000514071","article-title":"Immune dysfunction in patients with chronic lymphocytic leukemia and challenges during COVID-19 pandemic","volume":"144","author":"Langerbeins","year":"2021","journal-title":"Acta Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/16\/4447\/2239665\/blooda_adv-2024-012918-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/16\/4447\/2239665\/blooda_adv-2024-012918-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T15:31:34Z","timestamp":1724772694000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/16\/4447\/517527\/Ending-endless-follow-up-for-low-risk-CLL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":8,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,8,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024012918","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2024,8,27]]}}}